Xerostomia (Dry Mouth Disease) Therapeutics Market, Global Outlook and Forecast 2022-2028

April 2022 | 62 pages | ID: XB2D7E15CB15EN
Market Monitor Global

Abstracts

Xerostomia is a subjective feeling, caused by different reasons, many of the systemic many diseases are complications, some are the result of inevitable development. The side effect of the medicine is also one of the important factors that cause dry mouth. Xerostomia is a condition caused by a lack of saliva in the mouth. The amount of saliva in the mouth depends on the balance between production and consumption. If the amount of saliva produced is less than the amount consumed, there is a negative balance, indicating dry mouth.

This report contains market size and forecasts of Xerostomia (Dry Mouth Disease) Therapeutics in Global, including the following market information:

Global Xerostomia (Dry Mouth Disease) Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Xerostomia (Dry Mouth Disease) Therapeutics market was valued at 570.2 million in 2021 and is projected to reach US$ 668.4 million by 2028, at a CAGR of 2.3% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Artificial Saliva Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Xerostomia (Dry Mouth Disease) Therapeutics include Acacia Pharma, Church & Dwight, GlaxoSmithKline, Hikma Pharmaceuticals, Lupin, OraCoat, Parnell Pharmaceuticals, Pendopharm and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Xerostomia (Dry Mouth Disease) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Xerostomia (Dry Mouth Disease) Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Xerostomia (Dry Mouth Disease) Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Artificial Saliva
• Salivary Stimulants
• Saliva Substitutes
• Drugs
• Salivary Pens
• Others

Global Xerostomia (Dry Mouth Disease) Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Xerostomia (Dry Mouth Disease) Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Xerostomia (Dry Mouth Disease) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Xerostomia (Dry Mouth Disease) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Xerostomia (Dry Mouth Disease) Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Xerostomia (Dry Mouth Disease) Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Acacia Pharma
• Church & Dwight
• GlaxoSmithKline
• Hikma Pharmaceuticals
• Lupin
• OraCoat
• Parnell Pharmaceuticals
• Pendopharm
• Pfizer
• Sun Pharmaceutical Industries
• Synedgen

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Xerostomia (Dry Mouth Disease) Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL XEROSTOMIA (DRY MOUTH DISEASE) THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size: 2021 VS 2028
2.2 Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Xerostomia (Dry Mouth Disease) Therapeutics Players in Global Market
3.2 Top Global Xerostomia (Dry Mouth Disease) Therapeutics Companies Ranked by Revenue
3.3 Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Xerostomia (Dry Mouth Disease) Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Xerostomia (Dry Mouth Disease) Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Xerostomia (Dry Mouth Disease) Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Xerostomia (Dry Mouth Disease) Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Xerostomia (Dry Mouth Disease) Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Artificial Saliva
  4.1.3 Salivary Stimulants
  4.1.4 Saliva Substitutes
  4.1.5 Drugs
  4.1.6 Salivary Pens
  4.1.7 Others
4.2 By Type - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2021 & 2028
  5.1.2 Retail Pharmacies
  5.1.3 Hospital Pharmacies
  5.1.4 Online Pharmacies
5.2 By Application - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2017-2028
  6.3.2 US Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.3.3 Canada Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2017-2028
  6.4.2 Germany Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.4.3 France Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.4.5 Italy Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.4.6 Russia Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2017-2028
  6.5.2 China Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.5.3 Japan Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.5.6 India Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.7.3 Israel Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028
  6.7.5 UAE Xerostomia (Dry Mouth Disease) Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Acacia Pharma
  7.1.1 Acacia Pharma Corporate Summary
  7.1.2 Acacia Pharma Business Overview
  7.1.3 Acacia Pharma Xerostomia (Dry Mouth Disease) Therapeutics Major Product Offerings
  7.1.4 Acacia Pharma Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 Acacia Pharma Key News
7.2 Church & Dwight
  7.2.1 Church & Dwight Corporate Summary
  7.2.2 Church & Dwight Business Overview
  7.2.3 Church & Dwight Xerostomia (Dry Mouth Disease) Therapeutics Major Product Offerings
  7.2.4 Church & Dwight Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Church & Dwight Key News
7.3 GlaxoSmithKline
  7.3.1 GlaxoSmithKline Corporate Summary
  7.3.2 GlaxoSmithKline Business Overview
  7.3.3 GlaxoSmithKline Xerostomia (Dry Mouth Disease) Therapeutics Major Product Offerings
  7.3.4 GlaxoSmithKline Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 GlaxoSmithKline Key News
7.4 Hikma Pharmaceuticals
  7.4.1 Hikma Pharmaceuticals Corporate Summary
  7.4.2 Hikma Pharmaceuticals Business Overview
  7.4.3 Hikma Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Major Product Offerings
  7.4.4 Hikma Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Hikma Pharmaceuticals Key News
7.5 Lupin
  7.5.1 Lupin Corporate Summary
  7.5.2 Lupin Business Overview
  7.5.3 Lupin Xerostomia (Dry Mouth Disease) Therapeutics Major Product Offerings
  7.5.4 Lupin Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 Lupin Key News
7.6 OraCoat
  7.6.1 OraCoat Corporate Summary
  7.6.2 OraCoat Business Overview
  7.6.3 OraCoat Xerostomia (Dry Mouth Disease) Therapeutics Major Product Offerings
  7.6.4 OraCoat Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 OraCoat Key News
7.7 Parnell Pharmaceuticals
  7.7.1 Parnell Pharmaceuticals Corporate Summary
  7.7.2 Parnell Pharmaceuticals Business Overview
  7.7.3 Parnell Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Major Product Offerings
  7.7.4 Parnell Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Parnell Pharmaceuticals Key News
7.8 Pendopharm
  7.8.1 Pendopharm Corporate Summary
  7.8.2 Pendopharm Business Overview
  7.8.3 Pendopharm Xerostomia (Dry Mouth Disease) Therapeutics Major Product Offerings
  7.8.4 Pendopharm Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 Pendopharm Key News
7.9 Pfizer
  7.9.1 Pfizer Corporate Summary
  7.9.2 Pfizer Business Overview
  7.9.3 Pfizer Xerostomia (Dry Mouth Disease) Therapeutics Major Product Offerings
  7.9.4 Pfizer Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Pfizer Key News
7.10 Sun Pharmaceutical Industries
  7.10.1 Sun Pharmaceutical Industries Corporate Summary
  7.10.2 Sun Pharmaceutical Industries Business Overview
  7.10.3 Sun Pharmaceutical Industries Xerostomia (Dry Mouth Disease) Therapeutics Major Product Offerings
  7.10.4 Sun Pharmaceutical Industries Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global Market (2017-2022)
  7.10.5 Sun Pharmaceutical Industries Key News
7.11 Synedgen
  7.11.1 Synedgen Corporate Summary
  7.11.2 Synedgen Business Overview
  7.11.3 Synedgen Xerostomia (Dry Mouth Disease) Therapeutics Major Product Offerings
  7.11.4 Synedgen Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global Market (2017-2022)
  7.11.5 Synedgen Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Xerostomia (Dry Mouth Disease) Therapeutics Market Opportunities & Trends in Global Market
Table 2. Xerostomia (Dry Mouth Disease) Therapeutics Market Drivers in Global Market
Table 3. Xerostomia (Dry Mouth Disease) Therapeutics Market Restraints in Global Market
Table 4. Key Players of Xerostomia (Dry Mouth Disease) Therapeutics in Global Market
Table 5. Top Xerostomia (Dry Mouth Disease) Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Xerostomia (Dry Mouth Disease) Therapeutics Product Type
Table 9. List of Global Tier 1 Xerostomia (Dry Mouth Disease) Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Xerostomia (Dry Mouth Disease) Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Xerostomia (Dry Mouth Disease) Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Acacia Pharma Corporate Summary
Table 31. Acacia Pharma Xerostomia (Dry Mouth Disease) Therapeutics Product Offerings
Table 32. Acacia Pharma Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Church & Dwight Corporate Summary
Table 34. Church & Dwight Xerostomia (Dry Mouth Disease) Therapeutics Product Offerings
Table 35. Church & Dwight Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. GlaxoSmithKline Corporate Summary
Table 37. GlaxoSmithKline Xerostomia (Dry Mouth Disease) Therapeutics Product Offerings
Table 38. GlaxoSmithKline Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Hikma Pharmaceuticals Corporate Summary
Table 40. Hikma Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Product Offerings
Table 41. Hikma Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Lupin Corporate Summary
Table 43. Lupin Xerostomia (Dry Mouth Disease) Therapeutics Product Offerings
Table 44. Lupin Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. OraCoat Corporate Summary
Table 46. OraCoat Xerostomia (Dry Mouth Disease) Therapeutics Product Offerings
Table 47. OraCoat Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Parnell Pharmaceuticals Corporate Summary
Table 49. Parnell Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Product Offerings
Table 50. Parnell Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Pendopharm Corporate Summary
Table 52. Pendopharm Xerostomia (Dry Mouth Disease) Therapeutics Product Offerings
Table 53. Pendopharm Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Pfizer Corporate Summary
Table 55. Pfizer Xerostomia (Dry Mouth Disease) Therapeutics Product Offerings
Table 56. Pfizer Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Sun Pharmaceutical Industries Corporate Summary
Table 58. Sun Pharmaceutical Industries Xerostomia (Dry Mouth Disease) Therapeutics Product Offerings
Table 59. Sun Pharmaceutical Industries Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 60. Synedgen Corporate Summary
Table 61. Synedgen Xerostomia (Dry Mouth Disease) Therapeutics Product Offerings
Table 62. Synedgen Xerostomia (Dry Mouth Disease) Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Xerostomia (Dry Mouth Disease) Therapeutics Segment by Type in 2021
Figure 2. Xerostomia (Dry Mouth Disease) Therapeutics Segment by Application in 2021
Figure 3. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Xerostomia (Dry Mouth Disease) Therapeutics Revenue in 2021
Figure 8. By Type - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Xerostomia (Dry Mouth Disease) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Acacia Pharma Xerostomia (Dry Mouth Disease) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Church & Dwight Xerostomia (Dry Mouth Disease) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. GlaxoSmithKline Xerostomia (Dry Mouth Disease) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Hikma Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Lupin Xerostomia (Dry Mouth Disease) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. OraCoat Xerostomia (Dry Mouth Disease) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Parnell Pharmaceuticals Xerostomia (Dry Mouth Disease) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Pendopharm Xerostomia (Dry Mouth Disease) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Pfizer Xerostomia (Dry Mouth Disease) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Sun Pharmaceutical Industries Xerostomia (Dry Mouth Disease) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Synedgen Xerostomia (Dry Mouth Disease) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)